Data presented at the EORTC NCI AACR meeting detail data and progress on Millennium kinase programs: MLN8237 – Aurora A – Phase II trials expected in late 2008/early 2009 TAK-285 – … more →
Kinase NewsRChan wrote 3 months ago: A Montreal flavour this week… Critical link between EGFR and Src oncogenes: On the heels of la … more →
smnewsletters wrote 5 months ago: A randomized trial announced the recent annual meeting of the American Society of Clinical Oncology … more →
annalsofneurology wrote 5 months ago: Brain metastases in breast cancer patients tend to be a late event compared to other organs, sugge … more →
PKDnotes wrote 6 months ago: Everyone with PKD gets their GFR (Glomerular Filtration Rate, estimated or otherwise calculated) tes … more →
underwritingsolutionsllc wrote 7 months ago: Medical News: Two Tests Are Better Than One for Renal Disease Prognosis – in Nephrology, ESRD … more →
smnewsletters wrote 8 months ago: In people with atrial fibrillation, proteinuria increases the risk of stroke independent of other ri … more →
Paul Cacciatore wrote 9 months ago: “… ESR1 [gene] amplification is an uncommon mechanism for estrogen receptor overexpressi … more →
bmirtsching wrote 1 year ago: CORT has conducted research and treatment studies with the monoclonal anti-EGFR (anti-epidermal grow … more →
crimsoncanary wrote 1 year ago: Data presented at the EORTC NCI AACR meeting detail data and progress on Millennium kinase programs: … more →
crimsoncanary wrote 1 year ago: Boehringer have provided a pipeline update including information on kinase inhibitors, and announces … more →
crimsoncanary wrote 1 year ago: GSK have responded to the NICE recommendationi that Tyverb (lapatinib) should not be used in the NHS … more →
crimsoncanary wrote 1 year ago: Abbott have published a series of pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidine EGFR/ ErbB-2 Inhib … more →
crimsoncanary wrote 1 year ago: Phase II data presented at the European of Medical Oncology (ESMO) show that GSK’s Tykerb (lap … more →
crimsoncanary wrote 1 year ago: YM Biosciences have released Phase II data that show its EFGR antibody nimotuzumab to be effective i … more →
crimsoncanary wrote 1 year ago: Data to be presented at the AACR Centennial Conference on Translational Cancer Medicine today will d … more →
crimsoncanary wrote 1 year ago: Preclinical data presented at the European Society for Medical Oncology Conference show Hana Bioscie … more →
crimsoncanary wrote 1 year ago: In vitro studies with Src inhibitor AZD0530 and EGFR kinase inhibitor Geftinib show that treatment w … more →
crimsoncanary wrote 1 year ago: Takeda have submitted a New Drug Application to the Ministry of Health Labour and Welfare in Japan f … more →
crimsoncanary wrote 1 year ago: Data presented today at the 10th World Congress on Gastrointestinal Cancer shows that preemptive tre … more →